Domestic clinical cases  
In Japan, regenerative medicine has been carried out using our technology. We will present three examples of feedback from patients actually receiving treatment.
Case A is a 50 year old male with a rare cancer called nasal undifferentiated carcinoma. The cancer was too widespread and an operation could not be performed. Due to the danger of losing his eyesight, radiation therapy could not be performed and the use of anti-cancer drugs was refused. The patient was told that he had only half a year to live. The patient was rejected at all four hospitals, and began fusion cell therapy from May 2016. The cancer was dramatically reduced only by this therapy. He and his wife are living peacefully and healthily to this day

Medical history of subject A
  • November 2015: Swelling of the cheek and nasal stuffing was a subjective symptom.
  • December 2015: The cancer was diagnosed as undifferentiated carcinoma by biopsy. Development into the cerebrum was suspected. Further, due to the possibility of loss of eyesight and meningitis, it was determined that radiation and ion radiation therapy was impossible. Treatment with anti-cancer drugs was recommended, but the patient refused.
  • April 2016: At the time of a free consultation for fusion cell therapy, the right cheek to eyeball was projected and an odor from the nasal tumor was present.
  • May 2016: Fusion cell vaccine began.
  • June 2016: Nasal congestion slightly improved. Odor dissipated and the swelling in the cheek was reduced. Appetite was enhanced from about third injection of the vaccine. The patient conveyed at the time of fifth injection of vaccine that his “body condition was excellent” and “If I recovered to this point, I should have taken a photograph earlier”. Only fusion cell therapy was applied.

Case B is a 70 year old male who had stage II esophageal cancer. After surgery in March 2011, fusion cell therapy was performed. The cancer disappeared and five years have passed without a recurrence of the cancer. It has been five years in spring 2016 and the patient was completely recovered. Currently, he is still working for a company listed on the Tokyo Stock Exchange.

Medical history of subject B
  • July 2010: No abnormalities in annual examination.
  • December 2010: A feeling of something stuck in the throat when swallowing.
  • March 2011: With endoscopic examination, esophageal cancer was discovered. Esophageal cancer at stage II.
  • June 2011: Cervical esophagectomy, purging of 3 areas, large surgery of postmediastinal gastro tube reconstruction.
  • November 2011: Fusion cell therapy began.
  • Summer 2016: Five years have passed since the surgery. No metastasis and recurrence. The patient is more and more active.

Case C is of a 50 year old female. With the diagnosis of endometrial cancer at state IVb, peritoneal metastasis, cancerous peritonitis and multiple lymph node metastasis, the patient was told that she will have only 3 months to live. She was in a serious state. Despite treatment with anti-cancer drugs, total hysterectomy, and partial oophorectomy, the cancers spread through her system including kidneys and bladder. With the application of fusion cell therapy in May 2016, she made a miraculous rapid recovery. Now she lives very actively

Medical history of subject C
  • August 2015: Endometrial cancer screening at nearby gynecology and obstetrician (performed each year). Diagnosed to have no abnormalities.
  • November 2015: Hemorrhage from the uterus and fullness in the abdominal area.
  • November 2015: Accumulation of ascitic fluid and higher values of tumor markers (CEA, CA125)
  • December 2015: With CT analysis, tumor of endometrium, multiple lymph node metastasis, peritoneal metastasis (declaration of only 3 months to live). Treatment with anti-cancer drug TC began.
  • March 2016: A tendency of reduced tumor, total hysterectomy was performed.
  • March 2016: Free consultation at ACTI Clinic and ACTI Clinic Cooperative Medical Institution occured. She decided to go along with both treatment from anti-cancer drugs and the fusion cell vaccine.
  • May 2016: Fusion cell vaccine started.
  • June 2016: Cancers that had spread through the system of subject C almost disappeared. Tumor markers showed normal. TC therapy 6 courses were completed.

© Copyright 2017 CyTIX Inc. All rights reserved.